Amplitude-Modulated Radiofrequency Electromagnetic Fields (AM RF EMF) in Combination With Fruquintinib in Refractory Metastatic Colorectal Cancer (NCT07130903)

🧪 Interventions in This Study

• Fruquintinib (DRUG)
• TheraBionic P1 (DEVICE)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (9 Sites)

• Karmanos Cancer Institute at McLaren Bay Region — Bay City, Michigan
• Karmanos Cancer Institute at McLaren Clarkston — Clarkston, Michigan
• Karmanos Cancer Institute — Detroit, Michigan
• Karmanos Cancer Institute at McLaren Flint — Flint, Michigan
• Karmanos Cancer Institute at McLaren Greater Lansing — Lansing, Michigan
• Karmanos Cancer Institute at McLaren Lapeer Region — Lapeer, Michigan
• Karmanos Cancer Institute at McLaren Macomb — Macomb, Michigan
• Karmanos Cancer Institute at McLaren Northern Michigan, Petoskey — Petoskey, Michigan
• Karmanos Cancer Institute at McLaren Port Huron — Port Huron, Michigan

📞 Contact the Study Coordinator

Phone: (313) 576-8718

Email: alhallakm@karmanos.org

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Metastatic Colorectal Adenocarcinoma

• Fecal Microbiota Transplant and Re-introduction of Anti-PD-1 Therapy (Pembrolizumab or Nivolumab) for the Treatment of Metastatic Colorectal Cancer in Anti-PD-1 Non-responders — Houston, Texas
• Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study — Kingman, Arizona
• Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer — Gainesville, Florida
• Botensilimab Plus Balstilimab and Fasting Mimicking Diet Plus Vitamin C for Patients With KRAS-Mutant Metastatic Colorectal Cancer — Fullerton, California
• Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, The ERASur Study — Kingman, Arizona

Explore by condition: All Metastatic Colorectal Adenocarcinoma clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.